Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523534 | 0.87 | SLC2A1 (0.39) | NR1H4SLC2A1KDM4EALDH1A1 | |
| SCHEMBL3431629 | 0.84 | NR4A2 (0.46) | NR1H4SLC2A1GAATP53GABRD | |
| SCHEMBL3427891 | 0.78 | NR1H4 (0.47) | NR1H4SLC2A1GAATP53KDM4E | |
| SCHEMBL3435401 | 0.76 | NR1H4 (0.34) | NR1H4SLC2A1GAATP53GABRD | |
| SCHEMBL3430234 | 0.76 | NR1H4 (0.41) | NR1H4SLC2A1GAATP53GABRD | |
| SCHEMBL10106660 | 0.75 | NR4A2 (0.46) | KDM4EALDH1A1 | |
| SCHEMBL2064143 | 0.73 | NR4A2 (0.50) | — | |
| SCHEMBL3426757 | 0.72 | NR1H4 (0.41) | NR1H4SLC2A1GAATP53GABRD | |
| SCHEMBL2063436 | 0.70 | NR4A2 (0.53) | TP53KDM4EALDH1A1GFER | |
| SCHEMBL13269331 | 0.69 | ALOX5AP (0.38) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262805-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-20130123288-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (US) | 2013-05-16 | — | — | US | disclosed |
| US-8338451-B2 | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2262805-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009144395-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123288-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR1H4 400/4885SLC2A1 1107/4885GAA 167/4885 |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR1H4 400/4885SLC2A1 1107/4885GAA 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.